Windtree Therapeutics (WINT) Short Interest Ratio & Short Volume → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free WINT Stock Alerts $0.35 -0.01 (-2.75%) (As of 03/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Windtree Therapeutics Short Interest DataCurrent Short Volume30,500 sharesPrevious Short Volume58,400 sharesChange Vs. Previous Month-47.77%Dollar Volume Sold Short$10,370.00Short Interest Ratio / Days to Cover0.1Last Record DateMarch 15, 2024Outstanding Shares5,150,000 sharesFloat Size7,380,000 sharesShort Percent of Float0.41%Today's Trading Volume29,119 sharesAverage Trading Volume63,097 sharesToday's Volume Vs. Average46% Short Selling Windtree Therapeutics ? Sign up to receive the latest short interest report for Windtree Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatWINT Short Interest Over TimeWINT Days to Cover Over TimeWINT Percentage of Float Shorted Over Time Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. Windtree Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 3/15/202430,500 shares $10,370.00 -47.8%0.4%0.1 $0.34 2/29/202458,400 shares $21,024.00 -42.2%0.8%0.2 $0.36 2/15/2024101,100 shares $36,092.70 -56.0%1.9%0.3 $0.36 1/31/2024229,600 shares $96,500.88 +353.8%5.3%0.8 $0.42 1/15/202450,600 shares $28,953.32 +25.6%1.0%0.2 $0.57 12/31/202340,300 shares $28,975.70 +108.8%N/A0.3 $0.72 Get the Latest News and Ratings for WINT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/15/202319,300 shares $14,089.00 -55.5%0.5%0.2 $0.73 11/30/202343,400 shares $50,344.00 -13.4%1.1%0.4 $1.16 11/15/202350,100 shares $46,081.98 -22.5%1.2%0.5 $0.92 10/31/202364,600 shares $67,830.00 -65.8%1.5%0.5 $1.05 10/15/2023188,900 shares $236,125.00 +540.3%4.3%1.5 $1.25 9/30/202329,500 shares $27,983.70 +81.0%0.7%0.2 $0.95 9/15/202316,300 shares $18,745.00 +27.3%0.4%0.1 $1.15 8/31/202312,800 shares $14,095.36 -75.8%2.0%0.1 $1.10 8/15/202352,800 shares $85,536.00 +294.0%7.9%0.2 $1.62 7/31/202313,400 shares $18,626.00 +162.8%2.0%0 $1.39 7/15/20235,100 shares $6,834.00 -42.1%N/A0 $1.34 6/30/20238,800 shares $11,000.00 -90.5%N/A0 $1.25 6/15/202392,500 shares $142,450.00 -2.9%N/A0.1 $1.54 5/31/202395,300 shares $121,984.00 -51.2%N/A0.1 $1.28 5/15/2023195,100 shares $290,699.00 +64.4%N/A0.2 $1.49 4/30/2023118,700 shares $194,668.00 +136.9%68.7%0.1 $1.64 4/15/202350,100 shares $219,438.00 +87.6%8.5%0.1 $4.38 3/31/202326,700 shares $133,233.00 -2.9%4.7%0.2 $4.99 3/15/202327,500 shares $132,550.00 -53.0%4.9%0.3 $4.82 2/28/202358,500 shares $367,380.00 +604.8%10.3%0.6 $6.28 2/15/20238,300 shares $1,232.55 -98.9%N/A0.1 $0.15 1/31/2023754,800 shares $120,768.00 +16.1%N/A1.4 $0.16 1/15/2023650,300 shares $143,033.49 -28.2%N/A1.3 $0.22 12/30/2022905,900 shares $154,003.00 -28.7%N/A2 $0.17 12/15/20221,270,000 shares $226,060.00 +4.1%N/A1.4 $0.18 11/30/20221,220,000 shares $234,850.00 -3.2%N/A1.3 $0.19 11/15/20221,260,000 shares $110,250.00 -9.4%5.3%1.2 $0.09 10/31/20221,390,000 shares $238,385.00 -10.9%7.4%0.7 $0.17 10/15/20221,560,000 shares $379,704.00 +26.8%8.3%0.8 $0.24 9/30/20221,230,000 shares $369,123.00 +44.6%6.5%0.7 $0.30 9/15/2022850,900 shares $314,662.82 -8.3%4.5%0.6 $0.37 8/31/2022928,000 shares $365,632.00 +21.9%5.1%0.7 $0.39 8/15/2022761,500 shares $288,608.50 +0.0%4.2%0.6 $0.38 7/31/2022761,200 shares $299,913.56 -19.9%4.3%3.1 $0.39SHOCKING Crypto Leak… (Ad)A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. WINT Short Interest - Frequently Asked Questions What is Windtree Therapeutics' current short interest? Short interest is the volume of Windtree Therapeutics shares that have been sold short but have not yet been covered or closed out. As of March 15th, traders have sold 30,500 shares of WINT short. 0.41% of Windtree Therapeutics' shares are currently sold short. Learn More on Windtree Therapeutics' current short interest. What is a good short interest percentage for Windtree Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.41% of Windtree Therapeutics' floating shares are currently sold short. Is Windtree Therapeutics' short interest increasing or decreasing? Windtree Therapeutics saw a drop in short interest during the month of March. As of March 15th, there was short interest totaling 30,500 shares, a drop of 47.8% from the previous total of 58,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Windtree Therapeutics' float size? Windtree Therapeutics currently has issued a total of 5,148,000 shares. Some of Windtree Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Windtree Therapeutics currently has a public float of 7,380,000 shares. How does Windtree Therapeutics' short interest compare to its competitors? 0.41% of Windtree Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Windtree Therapeutics: TC Biopharm (Holdings) Plc (93.93%), Scinai Immunotherapeutics Ltd. (0.68%), Eloxx Pharmaceuticals, Inc. (1.49%), Avalon GloboCare Corp. (2.48%), Palisade Bio, Inc. (0.50%), Finch Therapeutics Group, Inc. (2.18%), NanoString Technologies, Inc. (12.55%), Fresh Tracks Therapeutics, Inc. (0.17%), Titan Pharmaceuticals, Inc. (2.21%), Creative Medical Technology Holdings, Inc. (3.14%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Cummins Inc. ($8.93 billion), Canadian Natural Resources Limited ($7.79 billion), Super Micro Computer, Inc. ($4.31 billion), T-Mobile US, Inc. ($4.00 billion), General Motors ($3.36 billion), Occidental Petroleum Co. ($3.10 billion), Charter Communications, Inc. ($2.92 billion), Coinbase Global, Inc. ($2.74 billion), Tractor Supply ($2.72 billion), and Moderna, Inc. ($2.31 billion). View all of the most shorted stocks. What does it mean to sell short Windtree Therapeutics stock? Short selling WINT is an investing strategy that aims to generate trading profit from Windtree Therapeutics as its price is falling. WINT shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Windtree Therapeutics? A short squeeze for Windtree Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of WINT, which in turn drives the price of the stock up even further. How often is Windtree Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including WINT, twice per month. The most recent reporting period available is March, 15 2024. More Short Interest Resources from MarketBeat Related Companies: TCBP Short Interest SCNI Short Interest ELOX Short Interest ALBT Short Interest PALI Short Interest FNCH Short Interest NSTG Short Interest FRTX Short Interest TTNP Short Interest CELZ Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:WINT) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaOnly a fool would buy Nvidia today… Porter & CompanyForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research Advisory